ARTV

3.7801.31%
FA

Fred Aslan

CEO, Principal Financial & Accounting Officer and Director

Dr. Fred Aslan, M.D. is Founder of Adavium Medical, Inc. and serves as its Director. Dr. Aslan serves as Chief Executive Officer and Director at Artiva Biotherapeutics, Inc. since January 2021, is its Principal Financial & Accounting Officer since May 18, 2026 and had been its President since January 2021 until May 18, 2026. Dr. Aslan serves as Chairman of the board of Vydence Medical. Prior to Artiva, Dr. Aslan was President and Chief Business Officer at Vividion Therapeutics, Inc. until December 31, 2020, where he was responsible for business development, finance, operations and alliance and project management. He had the opportunity to orchestrate Vividion’s Series B financing and upfront collaboration with Roche. Dr. Aslan served as a Vice President of VR Adviser, LLC. Dr. Aslan was with VR Adviser since 2006 and he specialized in investments in healthcare with a focus on biotechnology, diagnostics, medical devices and drug development sectors with a special interest in Latin America. He was a part of venture development team. Dr. Aslan had a 12 year affiliation with VR Adviser; initially as an investor from 2006 to 2013, when he co-founded and served as a board member of Receptos Pharmaceuticals (acquired by Celgene), led Venrock’s investment in Zeltiq (acquired by Allergan) and was involved in the early formation of Fate Therapeutics; and subsequently as an entrepreneur from 2013 to 2018, when he was CEO of Adavium Medical, a Brazilian medical device company, which he grew from zero to 350 employees, increased sales and established fully integrated R&D, manufacturing and commercial capabilities. He is the Founder and Chief Executive Officer of ADVANCE Medical, Inc. Dr. Aslan has strategic management and direct investment experience in the medical device, diagnostics and biotechnology sectors. His medical background combined with his business experience and has practical insights and advice to any healthcare entrepreneur. Prior to this, Dr. Aslan worked at Atlas Venture L.P. where he was involved in assessing new medical device and biotechnology investments. Prior to Atlas Venture, he served as Director of Business Development and Head of Investor Relations at CuraGen Corporation, where he was responsible for strategic planning, the in-licensing a clinical stage oncology compound, securing sell-side and buy-side interest and analyst coverage in it. Dr. Aslan worked as a Management Consultant at The Boston Consulting Group, Inc., where he advised biotechnology and pharmaceutical clients and companies. He had been a Director of Femasys Inc. since March 23, 2016. He serves as a Director of ADVANCE Medical, Inc. He served as a Director of Receptos, Inc. and as an observer in a number of other portfolio companies including Zeltiq and PowerVision. Dr. Aslan served as Director at Cytrellis Biosystems, Inc. until June 2026. Dr. Aslan has a twenty-year track record as an executive and investor in the life sciences industry. Dr. Aslan received an M.D. from Yale University School of Medicine in 1997-2001, an M.B.A. with distinction from the Harvard Business School in 2004-2006 and a B.S. in Biology from Duke University in 1993-1997.

Positions